Pfizer Q2 Results Beat Expectations, Raises Full-Year Revenue Floor to $60.5 Billion
Miles Bennett
Pfizer posted Q2 revenue of $15.03 billion and adjusted EPS of $0.77, both above Wall Street estimates, driven by strength in non-COVID products. The company raised its full-year revenue floor to $60.5 billion — but even the top end of its range barely matches last year's total.
How big was the beat?
Revenue hit $15.03 billion, topping the $14.41 billion consensus by $620 million. Adjusted EPS of $0.77 beat the $0.68 estimate by 13%.
This means → the outperformance was material, not a rounding-error beat.
The key signal: the upside came from non-COVID products, not a one-off bump in pandemic-era lines.
The guidance raise — why isn't it more bullish?
Pfizer lifted its full-year revenue floor from $59.5 billion to $60.5 billion. The new range is $60.5–62.5 billion.
In plain terms = the worst case got better, but the best case stayed the same.
Even the $62.5 billion ceiling barely matches 2025's $62.6 billion. This means → Pfizer's current growth story is about stopping the decline, not returning to high growth.
What is happening to COVID products?
Full-year revenue guidance for COVID products — vaccines plus Paxlovid — was cut from ~$5 billion to $4 billion, a 20% reduction.
This reflects continued shrinkage in COVID-product demand, a trend Pfizer itself no longer expects to reverse.
Full-year adjusted EPS guidance held steady at $2.80–3.00. In plain terms = the COVID shortfall will have to be offset by everything else in the portfolio.
What does Pfizer have to sustain the next leg?
Pfizer recently acquired obesity biotech Metsera for $10 billion, betting on the weight-loss space.
The most-watched catalyst: clinical data due this year on Pfizer's GLP-1 injectable — a class of drugs that mimic gut hormones to suppress appetite and lower blood sugar — combined with an amylin-class asset.
This means → whether non-COVID products keep scaling and whether pipeline data delivers will be the key checkpoints for any Pfizer re-rating.
Content is for reference only, not financial advice.